TaiMed Biologics Inc. (TPEX:4147)
49.25
+2.15 (4.56%)
May 29, 2026, 1:30 PM CST
TaiMed Biologics Revenue
TaiMed Biologics had revenue of 166.08M TWD in the quarter ending March 31, 2026, a decrease of -5.76%. This brings the company's revenue in the last twelve months to 601.19M, down -1.03% year-over-year. In the year 2025, TaiMed Biologics had annual revenue of 611.35M with 0.19% growth.
Revenue (ttm)
601.19M
Revenue Growth
-1.03%
P/S Ratio
22.38
Revenue / Employee
n/a
Employees
n/a
Market Cap
13.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 611.35M | 1.19M | 0.19% |
| Dec 31, 2024 | 610.16M | 118.39M | 24.07% |
| Dec 31, 2023 | 491.78M | -71.23M | -12.65% |
| Dec 31, 2022 | 563.01M | 149.57M | 36.18% |
| Dec 31, 2021 | 413.44M | -309.04M | -42.78% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sunmax Biotechnology | 2.04B |
| EirGenix | 1.13B |
| Ever Supreme Bio Technology | 1.03B |
| Medigen Vaccine Biologics | 603.68M |
| Tanvex BioPharma | 483.94M |
| Polaris Group | 69.27M |
| Gongwin Biopharm Holdings | 38.28M |
| AP Biosciences | 32.25M |